Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 1;2020(55):39-45.
doi: 10.1093/jncimonographs/lgz034.

Development and Utility of the Observational Research in Oncology Toolbox: Cancer Medications Enquiry Database-Healthcare Common Procedure Coding System (HCPCS)

Donna R Rivera  1 , Clara J K Lam  1 , Lindsey Enewold  2 , Valentina I Petkov  1 , Quyen Tran  1 , Sean Brennan  3 , Lois Dickie  1 , Timothy S McNeel  3 , Annie M Noone  1 , Bradley Ohm  3 , Dolly P White  2 , Joan L Warren  2 , Angela B Mariotto  1 , Lynne Penberthy  1
Affiliations

Development and Utility of the Observational Research in Oncology Toolbox: Cancer Medications Enquiry Database-Healthcare Common Procedure Coding System (HCPCS)

Donna R Rivera et al. J Natl Cancer Inst Monogr. .

Abstract

Purpose: Health-care claims are of increasing utility as a rich, real-world data resource for conducting treatment-related cancer research. However, multiple dynamic coding nomenclatures exist, leading to study variability. To promote increased standardization and reproducibility, the National Cancer Institute (NCI) developed the Cancer Medications Enquiry Database (CanMED)-Healthcare Common Procedure Coding System (HCPCS) within the Observational Research in Oncology Toolbox.

Methods: The CanMED-HCPCS includes codes for oncology medications that a) have a US Food and Drug Administration-approved indication for cancer treatment or treatment-related symptom management; b) are present in National Comprehensive Cancer Network guidelines; or c) carry an orphan drug designation for treatment or management of cancer. Included medications and their HCPCS codes were primarily identified based on Center for Medicare and Medicaid Services annual HCPCS Indices (2012-2018). To demonstrate the utility of the CanMED-HCPCS, use of systemic treatment for stage II-IV colorectal cancer patients included in the Surveillance, Epidemiology, and End Results-Medicare data (2007-2013) was assessed.

Results: The CanMED-HCPCS (v2018) includes 332 HCPCS codes for cancer-related medications: chemotherapy (156), immunotherapy (74), hormonal therapy (54), and ancillary therapy (48). Observed treatment trends within the NCI Surveillance, Epidemiology, and End Results-Medicare data were as expected; utilization of each treatment type increased with stage, and immunotherapy was largely confined to use among stage IV patients.

Conclusion: The CanMED-HCPCS provides a comprehensive resource that can be used by the research community to facilitate systematic identification of medications within claims or electronic health data using the HCPCS nomenclature and greater reproducibility of cancer surveillance and health services research.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Cancer Medication Enquiry Database-Healthcare Common Procedure Coding System (CanMED-HCPCS) Database Interface.
See this image and copyright information in PMC

References

    1. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF.. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(suppl 8):IV–3–18. - PubMed
    1. Center for Medicare and Medicaid Services (CMS). Medicare Claims Processing Manual. https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/.... Accessed November 21, 2018.
    1. Gilden DM, Kubisiak JM, Pohl GM, et al. Treatment patterns and cost-effectiveness of first line treatment of advanced non-squamous non-small cell lung cancer in Medicare patients. J Med Econ. 2017;20(2):151–161. - PubMed
    1. Eaton AA, Sima CS, Panageas KS.. Prevalence and safety of off-label use of chemotherapeutic agents in older patients with breast cancer: estimates from SEER-Medicare data. J Natl Compr Canc Netw. 2016;14(1):57–65. - PMC - PubMed
    1. Behera M, Ragin C, Kim S, et al. Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005. Cancer. 2016;122(1):50–60. - PMC - PubMed